Rethinking Testosterone Therapy After the FDA Label Revisions

madman

Super Moderator
Need to set up an account to log in and view the full webinar.




* For clinicians, the message is that screening and treating testosterone deficiency is good medicine, grounded in data rather than inherited fear.




1794866576674.webp

1794866591413.webp






Decades of fear about testosterone therapy rested on weak evidence, and the regulatory record is finally catching up with the science. Moderated by Dr. Amy Pearlman, this webinar brings together Dr. Abraham Morgentaler, Dr. Mohit Khera, and Dr. Helen Bernie, 3 members of the December 2025 FDA expert panel on testosterone therapy for men.

Dr. Morgentaler explains why the product label shapes prescribing across medicine, and traces how warnings about cardiovascular risk, age-related hypogonadism, and prostate cancer took hold. Dr. Khera recounts how the panel was organized. He also describes how the TRAVERSE trial led the FDA to remove the cardiovascular warning and request further revisions on prostate cancer, benign prostatic hyperplasia (BPH), and age-related use. Dr. Bernie makes the case that testosterone is an underused biomarker of men’s overall health, and describes her own research on testosterone, prostate-specific antigen, and recurrence after prostatectomy.

The panel also weighs the newly strengthened class-wide blood pressure warning, the burden of Schedule III status, and why the dogma linking testosterone to prostate cancer persisted for so long.
Throughout, the panelists emphasize counseling that is honest about modest risks without replacing one fear with another. In the later discussion, the faculty answer audience questions on defining treatment success, supraphysiologic levels, clomiphene and enclomiphene, and choosing among injectable, topical, pellet, and oral formulations. They close with their hopes for the next decade, including broader acceptance within medicine and approval of testosterone therapy for women.


For clinicians, the message is that screening and treating testosterone deficiency is good medicine, grounded in data rather than inherited fear.
 

ExcelMale Newsletter Signup

Beyond Testosterone Podcast

Online statistics

Members online
4
Guests online
1,740
Total visitors
1,744

Latest posts

Back
Top